Characteristics and Outcomes among Older HIV-Positive Adults Enrolled in HIV Programs in Four Sub-Saharan African Countries by Eduardo, Eduard et al.
Characteristics and Outcomes among Older HIV-Positive
Adults Enrolled in HIV Programs in Four Sub-Saharan
African Countries
Eduard Eduardo1, Matthew R. Lamb1,2*, Sasi Kandula2, Andrea Howard1,2, Veronicah Mugisha2,
Davies Kimanga3, Bonita Kilama4, Wafaa El-Sadr1,2, Batya Elul1,2
1 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, United States of America, 2 ICAP, Mailman School of Public
Health, Columbia University, New York, New York, United States of America, 3 National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya, 4 National
AIDS Control Program, Ministry of Health and Social Welfare, Dar es Salaam, Tanzania
Abstract
Background: Limited information exists on adults $50 years receiving HIV care in sub-Saharan Africa.
Methodology: Using routinely-collected longitudinal patient-level data among 391,111 adults $15 years enrolling in HIV
care from January 2005–December 2010 and 184,689 initiating ART, we compared characteristics and outcomes between
older ($50 years) and younger adults at 199 clinics in Kenya, Mozambique, Rwanda, and Tanzania. We calculated
proportions over time of newly enrolled and active adults receiving HIV care and initiating ART who were $50 years;
cumulative incidence of loss to follow-up (LTF) and recorded death one year after enrollment and ART initiation, and CD4+
response following ART initiation.
Findings: From 2005–2010, the percentage of adults $50 years newly enrolled in HIV care remained stable at 10%, while
the percentage of adults $50 years newly initiating ART (10% [2005]-12% [2010]), active in follow-up (10% [2005]-14%
(2010]), and active on ART (10% [2005]-16% [2010]) significantly increased. One year after enrollment, older patients had
significantly lower incidence of LTF (33.1% vs. 32.6%[40–49 years], 40.5%[25–39 years], and 56.3%[15–24 years]; p-value,
0.0001), but significantly higher incidence of recorded death (6.0% vs. 5.0% [40–49 years], 4.1% [25–39 years], and 2.8% [15–
24 years]; p-valve,0.0001). LTF was lower after vs. before ART initiation for all ages, with older adults experiencing less LTF
than younger adults. Among 85,763 ART patients with baseline and follow-up CD4+ counts, adjusted average 12-month
CD4+ response for older adults was 20.6 cells/mm3 lower than for adults 25–39 years of age (95% CI: 17.1–24.1).
Conclusions: The proportion of patients who are $50 years has increased over time and been driven by aging of the
existing patient population. Older patients experienced less LTF, higher recorded mortality and less robust CD4+ response
after ART initiation. Increased programmatic attention on older adults receiving HIV care in sub-Saharan Africa is warranted.
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Introduction
Recent UNAIDS and WHO data on the HIV epidemic show a
considerable increase in the number of people receiving antiret-
roviral therapy (ART), and sharp declines in both the number of
new infections and HIV-related deaths [1,2]. Consequently, the
number of people living with HIV (PLWH) [1,2] and their life
expectancy have increased to their highest levels [3]. These
accomplishments bring hope in the fight against the epidemic but
also new challenges.
Worldwide trends suggest a ‘‘graying’’ of the HIV epidemic
with an increasing proportion of PLWH aged 50 years or older. In
the United States, the proportion of older PLWH increased from
17% in 2001 to 24% in 2005 [4], and is projected to rise to 50%
by 2015 [5]. This demographic shift is not limited to resource-rich
settings. In 2011, 3.1 million adults 50 years or older were
estimated to be living with HIV in sub-Saharan Africa, accounting
for 13% of all infections in the region [6]. Given the aforemen-
tioned reduction in HIV-related mortality due to expansion of
ART use [1,2], coupled with the occurrence of secondary
incidence peaks of HIV acquisition among older adults in sub-
Saharan Africa [7], the number of older PLWH will likely
continue to increase in this region [6,8–10]. Despite this,
information on what accounts for this shift and the characteristics
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of and outcomes among older PLWH in sub-Saharan Africa
remains scant [8,11–13].
Older PLWH face unique challenges that may hinder timely
and effective HIV care and treatment. Symptoms of advanced
HIV disease (e.g. fatigue, weight loss, cognitive deficits) resemble
those associated with aging and therefore may result in delayed
HIV diagnosis, enrollment in care and initiation of treatment, a
common occurrence in sub-Saharan Africa and a leading cause of
HIV-related death [2,8,14,15]. Chronic conditions (e.g. hyperten-
sion, diabetes) associated with aging require treatment with
medications, augmenting the likelihood of drug-drug interactions
with ART and adverse drug reactions [16–18]. Furthermore,
immune recovery decreases with age, particularly for HIV-positive
individuals, as thymus function diminishes leading to increased risk
of immunologic failure and death [19–21]. Lastly, in sub-Saharan
Africa, older PLWH often face the financial and psychosocial
responsibility of raising grandchildren orphaned by HIV [22,23],
which may compromise engagement and retention in HIV care.
We used routinely-collected patient-level data from a large,
multi-country HIV program in sub-Saharan Africa to: (1) estimate
the proportion of all newly enrolled and active adult patients
receiving HIV care and initiating ART over time who were $50
years, and (2) compare key baseline characteristics and outcomes
between PLWH $50 years and ,50 years of age.
Materials and Methods
Study Population
The study population included patients $15 years of age
enrolled into HIV care between January 01, 2005 and December
31, 2010 and followed through December 31, 2011 at 199 health
facilities supported by ICAP at Columbia University through
funding from the President’s Emergency Plan for AIDS Relief
(PEPFAR). These included 69 facilities in Kenya, 52 in Tanzania,
44 in Rwanda and 34 in Mozambique. Provision of services at
each clinic was governed by respective national guidelines.
Data Sources
Patient information routinely collected at each clinic visit was
documented by clinicians on national patient forms, and regularly
entered into on-site electronic databases by data clerks. Informa-
tion was collected at enrollment and subsequent follow-up visits,
with visit frequency depending on patient CD4+ count and
whether they were receiving ART. Data quality assessments were
done at least annually at each health facility. Each quarter, these
electronic data were de-identified, encrypted, and imported into a
common-format database for analyses. Use of these de-identified
patient-level data for research purposes was approved by the
Columbia University Medical Center IRB and ethics committees
in each of the four countries where patients were enrolled.
Outcome definitions
The proportion of newly enrolled patients into HIV care and
ART initiation who were $50 years were calculated for each
quarter from 2005–2010. Patients were considered ‘‘active in
care’’ if they were not documented as dead, transferred, or lost to
follow-up (LTF) and if they had a recorded visit during the quarter
(ART patients) or during the current or prior three quarters (pre-
ART patients). Patients were followed until death, loss to follow-
up, transfer, or December 31, 2011, whichever occurred first.
Patients were considered LTF if they were not recorded as dead or
transferred and did not have a recorded visit date for six months
for ART patients or 12 months for pre-ART patients with no
subsequent recorded visit. ART patients LTF were censored 15
days after their last recorded visit and pre-ART patients were
censored 3 months after their last recorded visit. Patients with a
documented transfer to another facility were censored at their
transfer date.
Measures of HIV disease status (CD4+ cell count and WHO
stage) at enrollment into HIV care and ART initiation were
determined by assigning the closest recorded measure taken within
three months prior to or one month after enrollment or ART
initiation, as appropriate.
Statistical Analysis
Trends over time in the proportion of patients active in HIV
care or on ART were conducted after calculating each active
patient’s age at the beginning of a given quarter. For all other
analyses, patients were classified into four age groups (15–24, 25–
39, 40–49, and $50 years of age) based on their age at the time of
enrollment into care or ART initiation.
We assessed trends over time in the proportion of all adults who
were $50 years among the following groups using unadjusted log-
binominal regression: (1) patients newly enrolling in HIV care, (2)
patients newly initiating ART, (3) patients currently active in HIV
care, and (4) patients currently on ART.
Baseline characteristics and outcomes (LTF and recorded death)
through one year after enrollment into HIV care and ART
initiation were compared between age groups using generalized
linear mixed models and survival analytic techniques (Kaplan-
Meier and Cox proportional models with robust sandwich
estimators of variance), respectively. Comparisons of CD4+ cell
count at enrollment into care and ART initiation were performed
after log-transformation. CD4+ cell count response after ART
initiation was compared between age groups for the subset of
patients with a recorded CD4+ cell count at ART initiation and at
least one follow-up CD4+ cell count. Change in CD4+ cell count
after ART initiation was plotted as the median increase in CD4+
cell count by time after ART initiation, lagging each patient’s
recorded CD4+ count for up to three months or until the patient
had another CD4+ cell count or was censored from the analysis.
Statistical tests for differences in absolute overall change in CD4+
cell count after ART initiation by age group were conducted using
repeated-measures linear regression, adjusting for country, sex,
CD4+ count at ART initiation, year of ART initiation, facility
type and location.
IRB and ethical board approval for use of this routinely-
collected de-identified patient-level data has been given by the
Columbia University Medical Center IRB, the Kenya Medical
Research Institute Ethics Review Committee, the Comité
Nacional de Bioética para Saúde (Mozambican National Ethic
Committee), the Comite National de Pilotage des Recherches dans
le Domaine du VIH/SIDA in Rwanda (National Steering
Committee for HIV/AIDS Research in Rwanda), and the
National Institute for Medical Research in Tanzania. This study
involved the use of existing, routinely-collected de-identified
patient-level data and consequently was given a non-research
designation by the Columbia University Medical Center IRB and
country ethical review boards. No interviews were conducted, and
no data was collected independently for this study. Consequently,
informed consent was not necessary or obtained.
Results
Over the six-year period of observation, 392,131 patients $15
years of age enrolled in HIV care (Table 1), 184,689 (47%) of
whom initiated ART across the 199 health facilities (Table 2).
10% (N = 38,337) of the patients enrolling in HIV care and 11%
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(N = 21,108) of those initiating ART were $50 years of age. The
percentage of patients newly enrolling into HIV care who were $
50 years of age remained stable over time at around 10%
(P = 0.33), while the percentage of patients remaining in HIV care
who were $50 years increased from 10% to 14% over follow-up
period (P,0.0001). The percentage of patients newly initiating
ART who were $50 years increased from 10% to 12% (P,
0.0001) over the study period, and the percentage of patients
remaining active on ART who were $50 years increased from
10% to 16% (P,0.0001) (Figure 1).
Fifty percent of patients aged $50 were male compared with
45%, 32% and 15%, of those aged 40–49 years, 25–39 years, and
15–24 years, respectively. The proportion of patients aged $50
active in HIV care and on ART who were male decreased over
time (P,0.0001 for trend) (Figure 1). CD4+ cell counts at
enrollment into care and ART initiation were available for 51%
and 67% of all patients, respectively (Tables 1 and 2). At
enrollment into HIV care, median CD4+ cell count among older
patients was 224 cells/mm3 (IQR: 109–400) and was similar to
those aged 40–49 years (216 cells/mm3 [97–394]) but lower than
those aged 25–39 years (256 cells/mm3 [113–454]) and 15–24
years (377 cells/mm3 [199–593]) (P,0.0001 for overall difference
in medians) (Table 1). At ART initiation (Table 2), older patients
had slightly higher median CD4+ cell count (166 cells/mm3 [90–
245]) compared with adults aged 40–49 years (154 cells/mm3 [75–
234]) and those aged 25–39 years (159 cells/mm3 [74–242]), but
significantly lower than those aged 15–24 years (182 cells/mm3
[89–272]) (P,0.0001). Information on WHO stage was available
at enrollment into care and ART initiation for 72% and 57% of all
patients, respectively. Nearly two-thirds of patients with WHO
stage initiated treatment at WHO stage III or IV, with no
substantial differences between age groups. For each age stratum,
male patients initiated treatment at more advanced stages of HIV
disease as measured by CD4+ cell count. The proportion of
patients on treatment for tuberculosis at enrollment and at ART
initiation was similar across all age strata (Tables 1 and 2).
Half of the patients received HIV care in urban areas, and 64%
attended secondary or tertiary facilities, with little substantive
difference by age group. Point of entry into HIV care was similar
across age groups with the exception of those from prevention of
mother to child transmission (PMTCT) programs. Less than 1% of
patients $50 years of age were referred from PMTCT settings,
compared with 2%, 10%, and 21% of those aged 40–49, 25–39
and 15–24 years (Table 1).
Table 3 shows the cumulative incidence of LTF and recorded
death through one year after enrollment into HIV care and ART
initiation by age group. Cumulative incidence of LTF through one
year after enrollment into HIV care among patients $50 years of
age was similar (33.1%) to that observed among patients 40–49
years of age (32.6%), but significantly lower than that of younger
age groups (40.5% for adults 25–39 years and 56.3% for adults
15–24 years; P,0.0001 for difference between groups). Incidence
Figure 1. Proportion of adult patients 50 years and older, and proportion male, over time.
doi:10.1371/journal.pone.0103864.g001
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of recorded death was significantly higher among older patients
(6.0%) versus 5.0% for 40–49 years, 4.1% for 25–39 years, and
2.8% for 15–24 years (P,0.0001 for difference between groups).
Across all age groups, men experienced higher incidence of LTF
and death compared with women.
LTF after ART initiation was lower than after enrollment into
HIV care for all age and sex strata. Among patients who initiated
ART, cumulative incidence of LTF was similar among adults $50
years and those 40–49 years of age (16.1% and 15.3%,
respectively) but significantly lower than among younger age
groups (19.3% for adults 25–39 years and 28.0% for adults 15–24
years); P,0.0001 for difference between groups. Recorded death
through one year after ART initiation was highest among the
oldest age group (6.0%) compared with adults 40–49 years (5.1%),
25–39 years (4.5%), and 15–24 years (4.4%); P,0.0001 for
difference between groups. For each age-category, male patients
were more likely to be LTF and to have died within a year after
enrollment or ART initiation (Table 3).
Figure 2 presents CD4+ cell count response after ART
initiation for the 85,763 (46%) patients with CD4+ cell counts at
ART initiation and at least one follow-up CD4+ cell count.
Among these patients, older adults experienced smaller increases
in CD4+ cell count after ART initiation than all other age groups.
This result was observed overall and when stratified by gender.
After adjustment for baseline CD4+ cell count at ART initiation,
sex, year of ART initiation, facility type, location, and country,
compared to adults 25–39 years of age, the average CD4+ cell
increase at 12 months among adults $50 years was 20.6 cells/
mm3 lower (95% CI: 17.1 to 24.1 cells/mm3) (Table 4). The full
results of the regression results are in Table S1.
Discussion
Our study—which reports on the largest number of PLWH $
50 years of age enrolled in HIV programs in sub-Saharan Africa to
date—showed that the percentage of older adults newly initiating
ART and active in HIV care or on ART increased significantly
from 2006 to 2010, while the percentage of such patients newly
enrolling in HIV care remained stable during that period. These
findings suggest that the observed increases in the percentage of
patients aged $50 years initiating ART, and remaining active in
care is resulting from a ‘‘graying’’ of the existing patient
population rather than new enrollment of older patients. We
found that approximately 14% and 16% of adult patients active in
HIV care and on ART, respectively, were $50 years of age at the
end of 2010, similar to population estimates of the percentage of
older PLWH in sub-Saharan Africa [24]. Furthermore, in our
analyses, 12% of the adult population newly initiating ART were
$50 years of age at the end of 2010, similar to estimates from a
recent study which included data from nine countries in sub-
Saharan Africa [25].
We observed that patients $50 years of age enrolling into HIV
care and initiating ART were more likely to be male compared to
younger adults, which were disproportionately female. Our
findings of disproportionately higher proportions of males among
older adults compared to younger adults accessing HIV care is
consistent with findings from a retrospective cohort study in
Zomba District, Malawi [26], which compared adults 25–49 years
of age at ART initiation to those 50 years and older, and the
DART clinical trial in Zimbabwe and Uganda [27], which
compared symptomatic (WHO stage 2–4) adults at ART initiation
with CD4+ cell counts ,200 cells/mm3 18–49 years of age to
those 50 years and older. We extend these studies by additionally
presenting higher proportions of older adults enrolling in HIV care
who are male, in addition to the findings at ART initiation, and by
further stratifying into age categories of 15–24 years, 25–39 years
and 40–49 years to highlight that the proportion male increases
with each increasing age category.
The predominance of active males among patients $50 years in
HIV care or on ART remained even though males were more
likely to die or become LTF. This gender differential may reflect a
higher prevalence of HIV among males $50 years, consistent with
epidemiologic surveys in South Africa [28], and/or delayed
Table 3. Loss to follow-up and death one year after enrollment into care and ART initiation, by age group.
Cumulative incidence* of loss to follow-up and recorded death one year after enrollment into HIV care** n = 392,131
% Loss to follow-up % Recorded Dead
Age Group
(years) Overall Males Females Overall Males Females
$50 33.1 35.9 30.5 6.0 7.3 4.7
40–49 32.6 36.5 29.4 5.0 6.5 3.9
25–39 40.5 46.1 38.0 4.1 5.9 3.3
15–24 56.3 58.5 55.9 2.8 4.3 2.5
Cumulative incidence* of loss to follow-up and recorded death one year after ART initiation** n = 184,689
% Loss to follow-up % Recorded Dead
Age Group
(years) Overall Males Females Overall Males Females
$50 16.1 17.8 14.5 6.0 7.1 4.8
40–49 15.3 17.5 13.6 5.1 6.4 4.1
25–39 19.3 24.1 17.2 4.5 6.6 3.6
15–24 28.0 32.9 26.9 4.4 5.6 4.1
*Cumulative incidence of loss to follow-up and death estimated using Kaplan-Meier survival analytic techniques.
**Log-rank test for equality over strata statistically significant for all models at an alpha of 0.05.
doi:10.1371/journal.pone.0103864.t003
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engagement in care among men. As shown in our analyses and the
published literature, male patients in resource-limited settings
present for care at more advanced stages of HIV disease and
therefore are more likely to initiate treatment late [29–31].
The imbalance in gender distribution by age does not
completely explain the disparity in mortality between older and
younger adults. Age-stratified analyses showed that mortality was
higher and CD4+ cell response was less robust among older adults
for both men and women when compared to younger PLWH,
similarly to results described elsewhere [25]. Information on cause
of death was unavailable, and it is likely that at least some of the
increased mortality among older adults is due to increased
background risk of death from natural aging processes. Addition-
ally, differences in CD4+ cell count response may contribute to the
higher mortality observed among older patients. Indeed, although
older adults had slightly higher average CD4+ cell counts at ART
initiation compared to adults 40–49 years and adults 25–39 years,
older adults experienced significantly lower CD4+ cell count
response than younger patients after ART initiation. Studies have
shown discrepant findings, with some showing similar results to
ours [25,32], and others finding comparable CD4+ cell count
responses in older and younger adults [33,34]. However, with the
Figure 2. Change in CD4+ cell count after ART initiation, by age category. 2a. All Patients. 2b. Males. 2c. Females.
doi:10.1371/journal.pone.0103864.g002
Table 4. Multivariate regression: Relative increase in CD4+ cell count (cells/mm3) after ART initiation, n = 85,763.
Model11 Model22
Age Group Change in CD4 95% CI Change in CD4 95% CI
$50 years 233.9 (230.2 to 237.6) 220.6 (217.1 to 224.1)
40–49 years 212.7 (29.8 to 215.6) 28 (25.2 to 210.7)
25–39 years Reference
15–24 years 1.3 (24.3 to 6.8) 5.5 (0.4 to 10.5)
1 Controls for timing of CD4 measure after ART initiation and within-clinic correlation.
2 Additionally controls for clinic type and location, country, sex, year of ART initiation, and CD4 at ART initiation.
doi:10.1371/journal.pone.0103864.t004
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exception of the study by Grieg et al [25], all of the latter studies
were conducted in resource-rich countries where adults may have
a different baseline clinical profile than that of our population.
Our findings on reduced CD4+ cell response after ART initiation
among older adults are similar to those noted by Grieg et al [25]
by demonstrating that this decreased response remains up to 36
months after ART initiation, and that the decreased response
remained even after adjustment for factors potentially associated
with differential CD4+ cell response post ART initiation.
Our study has a number of strengths. To our knowledge, it is
the largest multi-country study investigating characteristics and
outcomes of older PLWH enrolling in HIV care in sub-Saharan
Africa. The data used in this study were derived from health
facilities that are in many ways typical of HIV care settings in the
region. Some limitations must be noted, however. Only 67% of
patients had a CD4+ cell count at ART initiation and of these,
only 67% had at least one post-ART CD4+ cell count. Patients
missing CD4+ cell counts at ART initiation were similar to
patients with CD4+ cell counts at ART initiation in facility
location, year of ART initiation, point of entry, sex, and WHO
stage at ART initiation. However, patients initiating ART in
Rwanda were significantly more likely to have ART initiation
CD4+ cell counts (86%) compared to patients enrolling in Kenya
(72%), Mozambique (62%), and Tanzania (61%). While it is
possible that individuals with ART initiation and follow-up CD4+
cell counts differ on CD4 response from those with missing ART
initiation and/or follow-up CD4+ cell counts, it is unlikely that this
difference would be substantially differential by age category,
suggesting this is an unlikely explanation for the observed
difference in CD4 response between older and younger adults.
Further, our findings are similar to those of another multi-country
analysis in Africa [25]. Additionally, we lacked information on co-
morbidities which may increase with age, and thus were unable to
explore whether they contributed to the higher death rates
observed among patients aged $50 years of age. Lastly, a large
proportion of patients were LTF, especially among younger adults.
Whether these patients stopped treatment, transferred to another
facility or died is unknown. Since some proportion of patients
deemed LTF in our analyses are likely to be unrecorded deaths
[35,36], we expect that the true death rate in our population is
likely higher than documented in our data.
Conclusions
This analysis found that, across a large population including 199
health facilities in 4 sub-Saharan African countries, increasing
proportions of adults newly initiating ART, and active in HIV care
and on ART, are 50 years and older. These older adults are at
increased risk of death, at lower risk of loss to follow-up and have
less robust CD4+ cell count response after initiation of ART.
Given trends in increasing representation of older adults among
the population seeking HIV care in sub-Saharan Africa, there is
the need to better understand CD4+ cell count response and to
identify programmatic features associated with enhanced out-
comes of older patients on treatment.
Supporting Information
Table S1 Complete results of regression analysis: change in
CD4+ cell count after ART initiation.
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